The study will collect clinical data on patients who receive the Caris Chromoseq assay for an underlying hematologic malignancy. The assay provides risk stratification for patients with acute myeloid leukemia (AML) myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN). The hypothesis of the study is that Caris Chromoseq compares favorably to conventional cytogenetics, FISH, and NGS analysis in terms of risk stratification capabilities, ease of use, and turnaround time.
Stated willingness to comply with all study procedures and availability for the duration of the study and has signed consent form
Subject must be 18 or older
Subject be diagnosed with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or myeloproliferative neoplasms (MPN)
Physician must order or plan to order Caris Chromoseq for their patient
Patient for whom Caris Chromoseq is not being ordered
Patient is pregnant or lactating
Patient is not able or willing to provide consent to data collection for this protocol